Company intelligence / Profile preview

ViaDerma, Inc.

Marina Del Rey, California, United Statesviaderma.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

ViaDerma's lead product Vitastem is an FDA-registered topical antibiotic that utilizes an innovative transdermal delivery method. It has undergone over 10 years of clinical testing and is reported to kill all harmful bacteria available for testing, delivering results within 24 hours compared to 5-7 days for other products[1][2].

Therapeutic areas: Men's HealthOncologyEndocrinologyOtherDermatologyNeurologyInfectious Diseases
Modalities: Topical antibioticsTransdermal delivery systems
Industry: Biotech

Drug pipeline

3 assets

Nupelo

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ViaDerma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViaDerma, Inc..

Explore the full profile